Shots:

• Cancer Research UK to get upfront in cash and equity- success-based milestones- royalties and will fund & sponsor the development of BT7401 from preclinical to the P-IIa trial. Bicycle to get rights to advance BT7401 program
• The focus of the collaboration is to get insights on biologic and therapeutic profile of BT7401 candidate which can be used for patients who stop responding to checkpoint inhibitors
• BT7401 is a multivalent Bicycle CD137 agonist and has shown durable anti-tumor effects with significant pharmacologic activity in preclinical models. Bicycle’s BT1718 is also a Bicycle Toxin Conjugate (BTC) that targets MT1-MMP and is evaluated in P-I/IIa trial

Click here to read full press release/ article | Ref: Bicycle Therapeutics | Image: Twitter